Altimmune Inc (ALT)
7.03
-0.05
(-0.71%)
USD |
NASDAQ |
Apr 25, 11:29
Altimmune Cash from Operations (Quarterly): -16.53M for Dec. 31, 2023
Cash from Operations (Quarterly) Chart
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | -16.53M |
| September 30, 2023 | -20.49M |
| June 30, 2023 | -19.38M |
| March 31, 2023 | -19.41M |
| December 31, 2022 | -17.31M |
| September 30, 2022 | -15.05M |
| June 30, 2022 | -16.70M |
| March 31, 2022 | -13.53M |
| December 31, 2021 | -21.97M |
| September 30, 2021 | -17.78M |
| June 30, 2021 | -18.93M |
| March 31, 2021 | -19.57M |
| December 31, 2020 | -13.28M |
| September 30, 2020 | -9.505M |
| June 30, 2020 | -7.171M |
| March 31, 2020 | -4.347M |
| December 31, 2019 | -2.002M |
| September 30, 2019 | -2.427M |
| June 30, 2019 | -3.060M |
| March 31, 2019 | -2.113M |
| December 31, 2018 | -5.155M |
| September 30, 2018 | -1.023M |
| June 30, 2018 | 0.3481M |
| March 31, 2018 | -3.559M |
| December 31, 2017 | -4.806M |
| Date | Value |
|---|---|
| September 30, 2017 | -4.259M |
| June 30, 2017 | -7.806M |
| March 31, 2017 | -3.343M |
| December 31, 2016 | -1.493M |
| September 30, 2016 | -1.893M |
| June 30, 2016 | -1.612M |
| March 31, 2016 | -1.355M |
| December 31, 2015 | -1.829M |
| September 30, 2015 | -1.327M |
| June 30, 2015 | 2.653M |
| March 31, 2015 | -2.713M |
| December 31, 2014 | -3.522M |
| September 30, 2014 | -2.124M |
| June 30, 2014 | -0.5333M |
| March 31, 2014 | -2.294M |
| December 31, 2013 | -6.256M |
| September 30, 2013 | -0.6767M |
| June 30, 2013 | -0.4954M |
| March 31, 2013 | 0.2604M |
| December 31, 2012 | -2.145M |
| September 30, 2012 | 1.734M |
| June 30, 2012 | -2.704M |
| March 31, 2012 | 0.7914M |
| December 31, 2011 | -0.8051M |
| September 30, 2011 | -3.618M |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (Quarterly) Range, Past 5 Years
-21.97M
Minimum
Dec 2021
-2.002M
Maximum
Dec 2019
-13.60M
Average
-16.53M
Median
Dec 2023
Cash from Operations (Quarterly) Benchmarks
| Eli Lilly and Co | -311.90M |
| Amgen Inc | 538.00M |
| Viking Therapeutics Inc | -17.64M |
| Precision BioSciences Inc | -8.423M |
| Terns Pharmaceuticals Inc | -19.32M |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | -7.959M |
| Cash from Financing (Quarterly) | 72.75M |
| Free Cash Flow | -75.86M |
| Free Cash Flow Per Share (Quarterly) | -0.2826 |
| Free Cash Flow to Equity (Quarterly) | -16.53M |
| Free Cash Flow to Firm (Quarterly) | -16.53M |
| Free Cash Flow Yield | -20.27% |